Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SHP623 in healthy adults
NCT02663687Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2016
- Primary completion
- Dec 2016
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hereditary angioedema (HAE) comparing SHP623 with Placebo (2 arms). Primary endpoint: Number of Participants With Treatment-emergent Adverse Events Including Serious Adverse Events up to 28 days. Started Feb 2016; status: completed.
02
Drugs
SHP623
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT02663687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02663687.